We are excited to share that a new case report is available in pre-print detailing a successful treatment of Corticobasal Syndrome (CBS), a rare and progressive neurodegenerative condition for which there have previously been no effective therapies.
What is CBS?
CBS is a devastating illness, often misdiagnosed and commonly associated with rapid decline. Symptoms can include rigidity, tremors, myoclonus, aphasia, alien hand syndrome, dementia, and other severe neurological impairments. With no current proven treatments, CBS is considered terminal, and patients are often told little can be done.
The case study at a glance
In this upcoming publication, our team—including Dr. Craig Tanio, Denise Nonelle, APRN, Millicent Sydnor, and Dr. Dale Bredesen—reports the case of a 59-year-old veteran who developed CBS after significant toxic exposures during military service.
She underwent a personalized, precision medicine approach that included:
- Detoxification strategies
- Bioidentical hormone optimization
- Brain training
- Hyperbaric oxygen therapy
- Diet and lifestyle interventions
The patient’s progress was not only evident clinically but was also supported by multiple objective measures, confirming both functional and structural improvements in brain health. Key findings included:
- Cognitive Function: Montreal Cognitive Assessment (MoCA) score improved significantly, rising from 21/30 to 28/30.
- Motor Recovery: Restoration of motor function in the affected hand, including fine motor control.
- Neurophysiology: Quantitative EEG (qEEG) findings normalized, indicating improved electrophysiological function.
- Neuroimaging: MRI volumetric analysis demonstrated measurable structural changes in the brain.
Why this is Groundbreaking
This is the first documented case demonstrating that CBS symptoms can be significantly reversed using an integrative, precision medicine protocol. The results suggest that toxic exposures and metabolic imbalances may play a larger role in CBS than previously recognized, and that targeted interventions could provide hope for patients previously left without options.
What’s next
This case report points to a need for larger clinical trials to evaluate toxin-targeted, precision medicine approaches for CBS and related neurodegenerative disorders. The upcoming report release is only the beginning—we anticipate this work will help shift the landscape of how these difficult conditions are approached in clinical practice.
Stay Tuned
The full preprint, “Successful Treatment of Corticobasal Syndrome: Case Study”, is now available on Preprints.org (doi: 10.20944/preprints202508.2207.v1). It will be indexed in Web of Science, Google Scholar, Crossref, and Europe PMC—making it accessible worldwide.
This report represents a new direction in neurodegenerative medicine—and a ray of hope for patients and families affected by CBS and related neurodegenerative disorders. It also highlights the need for further research on how toxicants can affect multiple types of neurodegenerative disorders such as Parkinson’s.
